Alemtuzumab in MS: 6-Year Data Reassuring Alemtuzumab in MS: 6-Year Data Reassuring

Data continue to show strong durable efficacy with reassuring safety, which experts say should increase confidence in using the drug for early disease, where its benefit is greatest.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news